Mark L. Baum, J.D., Founder

Chief Executive Officer, Member, Board of Directors

Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals, a commercial stage pharmaceutical company focused on providing patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. Mr. Baum is also a founder and board member of Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and accessibility issues has been featured in Op-Ed contributions for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. Mr. Baum is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

Stay Connected

Imprimis Pharmaceuticals, Inc.
Investor Relations
12264 El Camino Real, Suite 350
San Diego, CA 92130
T: 858.704.4040 | F: 858.345.1745

Contact Us Today


Stay Informed

Interested in receiving investor news and updates?

Click Here

Download Imprimis’ IR App for smart phones and tablets for the latest news, reports, presentations and more.